Diphenylamine Derivatives Modulating Potassium Channels and TRPV1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents are inadequate in effectively modulating potassium channels and TRPV1 receptors for treating various pathologies related to neuronal excitability, pain, and other medical conditions.
Innovation Solution
Development of novel compounds based on diphenylamine derivatives with electron-withdrawing substituents that act as potassium channel openers or blockers, and TRPV1 modulators, specifically designed to interact with specific binding sites on these channels to alter their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used to modulate potassium channels and TRPV1 receptors, then treatment of various pathologies is attempted, but the agents are inadequate in effectively modulating these channels and receptors
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of diphenylamine derivatives through varying substituents (electron-withdrawing groups at different positions and types) to optimize the balance between channel modulation effectiveness and therapeutic versatility. This structural parameter optimization enables the compounds to effectively modulate multiple channel types (KCNQ2, KCNQ3, TRPV1) with a single agent.
2Reliability
If compounds are designed to interact with specific binding sites on potassium channels and TRPV1, then selective modulation is achieved, but complexity of compound design increases
Solution Approach 1:
The patent applies local quality by introducing specific electron-withdrawing substituents at particular positions (R2-R10) on the diphenylamine core structure. These localized structural modifications create specific interaction characteristics with binding sites on potassium channels and TRPV1, achieving selective modulation without requiring complex overall molecular architecture.
3Adaptability or versatility
If compounds modulate multiple channel types (KCNQ2, KCNQ3, TRPV1), then broader therapeutic benefits are achieved, but risk of adverse effects on other channels increases
Solution Approach 1:
The patent applies universality by designing diphenylamine derivative compounds that can interact with multiple channel types (KCNQ2, KCNQ3, TRPV1) through a common structural mechanism. The electron-withdrawing substituted diphenylamine core provides a universal binding mode that achieves broad therapeutic coverage while maintaining selectivity through optimized substituent patterns that minimize off-target effects on non-intended channels like TRPV6.
Data Source
AI summary
Compounds that can be used as openers or blockers of voltage-dependent potassium channels, and which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing or enhancing cortical and/or peripheral neuron activity, compositions containing same and methods utilizing same are disclosed. Also disclosed are modulators of voltage-dependent potassium channels, which exhibit blocking of a TRPV1 channel, and hence are useful in the treatment of TRPV1-related conditions.